Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01014208 · ClinicalTrials.gov registry record · Phase 3
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 447
- Enrollment target
NCT01014208 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 447 participants.
The verdict
NCT01014208, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 447 participants
- Enrollment target
Study Summary
This study is being conducted to compare the efficacy and safety of ofatumumab in addition to salvage chemotherapy versus rituximab in addition to salvage chemotherapy in CD20 positive DLBCL subjects relapsing, or with persistent disease, after first-line treatment with rituximab combined with an anthracycline-based chemotherapy regimen and be eligible for ASCT.
Interventions
- DRUG OFATUMUMAB + DHAP
- DRUG RITUXIMAB + DHAP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 447 participants |
| Start Date | 2010-03 |
| Est. Completion | 2014-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01014208
The ClinicalTrials.gov registry entry for NCT01014208 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 447 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which OFATUMUMAB + DHAP is the first listed.
NCT01014208 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01014208 about?
NCT01014208 is a clinical study titled "Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma". This study is being conducted to compare the efficacy and safety of ofatumumab in addition to salvage chemotherapy versus rituximab in addition to salvage chemotherapy in CD20 positive DLBCL subjects relapsing, or with persistent disease, after first-line treatment with rituximab combined with an an...
What is the current status of trial NCT01014208?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 447 participants. The study started on 2010-03. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01014208?
The interventions under investigation include: OFATUMUMAB + DHAP (DRUG), RITUXIMAB + DHAP (DRUG).
Who is sponsoring clinical trial NCT01014208?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.